Chemotherapy plus targeted therapies shows improved survival in advance-stage lung cancer patients

The combination of traditional chemotherapy agents with targeted therapies called monoclonal antibodies showed no safety concerns and improved survival in patients with advanced non-small cell lung cancer according to a study presented at the 2008 Chicago Multidisciplinary Symposium in Thoracic Oncology.

Read the whole article on Physorg

More from Physorg